Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v3.23.3
Stock-Based Compensation
9 Months Ended
Sep. 30, 2023
Stock-Based Compensation, Restricted Stock and Stock Options [Abstract]  
Stock-Based Compensation

Note 12 – Stock-Based Compensation

 

Stock Options 

 

The Company grants equity-based compensation under its 2020 Long-Term Incentive Plan (the “2020 Plan”) and its 2016 Equity Incentive Plan (the “2016 Plan”). The 2020 Plan and 2016 Plan allows the Company to grant incentive and nonqualified stock options, and shares of restricted stock to its employees, directors and consultants. On June 14, 2019, the Board of Directors of the Company approved increasing the number of shares allocated to the Company’s 2016 Equity Incentive Plan from 91,667 to 122,222.

 

On December 16, 2020, the Company adopted its 2020 Plan. Under the 2020 Plan, there are 88,889 shares of the Company’s common stock available for issuance and the 2020 Plan has a term of 10 years.

 

Under the 2016 Plan and the 2020 Plan, upon the exercise of stock options and issuance of fully vested restricted common stock, shares of common stock may be withheld to satisfy tax withholdings. The Company intends to net settle certain employee options to ensure adequate authorized shares under the Incentive Plan.

 

On December 22, 2022, the Company adopted its 2022 Long-Term Incentive Plan (the “2022 Plan”). Under the 2022 Plan, there are 70,000 shares of the Company’s common stock available for issuance and the 2022 Plan has a termination date of October 31, 2032.

 

A summary of activity under the Plans for the nine months ended September 30, 2023 is as follows:

 

    Shares
Underlying
Options
    Weighted
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
Term
(Years)
    Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2022     159,295     $ 153.35       6.5     $ 26,188  
Forfeited     (1,516 )   $ 196.86      
-
      -  
Outstanding at September 30, 2023     157,779     $ 157.47       5.8     $
-
 
                                 
Exercisable at September 30, 2023     143,325     $ 168.04       5.5     $
-
 

 

Stock-Based Compensation

 

The total stock-based compensation expense recognized was as follows (in thousands):

 

    Three months ended
September 30,
    Nine months ended
September 30,
 
    2023     2022     2023     2022  
                         
Research and development expenses   $ 46     $ 136     $ 150     $ 636  
Selling, general and administrative expenses     87       344       296       2,375  
Total stock-based compensation   $ 133     $ 480     $ 446     $ 3,011  

 

As of September 30, 2023, the total unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was $0.1 million, which the Company expects to recognize over an estimated weighted-average period of 2.5 years. 

 

Restricted Stock Units

 

A summary of the Company’s restricted stock activity and related information is as follows:

 

    Number of
Shares
    Weighted
Average
Grant-Date
Fair Value
 
Unvested at December 21, 2022     10,483     $ 82.02  
Vested     (3,344 )   $ 104.04  
Unvested at September 30, 2023     7,139     $ 71.68